Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Recommendation of “Hold” from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) has earned an average recommendation of “Hold” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $40.6667.

A number of research firms have commented on AGIO. Leerink Partners raised their price target on Agios Pharmaceuticals from $34.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, December 26th. Truist Financial increased their price objective on shares of Agios Pharmaceuticals from $32.00 to $38.00 and gave the company a “buy” rating in a report on Wednesday, December 24th. Royal Bank Of Canada cut shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $57.00 to $28.00 in a research report on Wednesday, November 19th. The Goldman Sachs Group reduced their price target on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a report on Thursday, November 20th. Finally, JPMorgan Chase & Co. lifted their target price on Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, January 6th.

Agios Pharmaceuticals Trading Down 1.8%

Shares of NASDAQ:AGIO opened at $27.68 on Friday. The stock has a 50 day moving average of $28.07 and a 200 day moving average of $33.33. The company has a market cap of $1.62 billion, a PE ratio of -3.89 and a beta of 0.89. Agios Pharmaceuticals has a 12-month low of $22.24 and a 12-month high of $46.00.

Insider Transactions at Agios Pharmaceuticals

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,932 shares of the company’s stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total value of $79,427.88. Following the transaction, the chief financial officer owned 37,394 shares of the company’s stock, valued at $1,013,003.46. This represents a 7.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider James William Burns sold 2,932 shares of the company’s stock in a transaction dated Tuesday, December 30th. The stock was sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the transaction, the insider owned 31,718 shares in the company, valued at approximately $859,240.62. The trade was a 8.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 33,303 shares of company stock worth $901,977 in the last quarter. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On Agios Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. AQR Capital Management LLC boosted its holdings in shares of Agios Pharmaceuticals by 66.8% in the first quarter. AQR Capital Management LLC now owns 51,489 shares of the biopharmaceutical company’s stock valued at $1,498,000 after purchasing an additional 20,625 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Agios Pharmaceuticals by 7.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,327 shares of the biopharmaceutical company’s stock worth $1,274,000 after buying an additional 2,920 shares during the period. NewEdge Advisors LLC purchased a new stake in shares of Agios Pharmaceuticals in the 1st quarter worth $40,000. Goldman Sachs Group Inc. grew its position in shares of Agios Pharmaceuticals by 16.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 658,652 shares of the biopharmaceutical company’s stock worth $19,299,000 after buying an additional 91,482 shares in the last quarter. Finally, Woodline Partners LP purchased a new position in shares of Agios Pharmaceuticals during the first quarter valued at $597,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.